Organon Pharma Indonesia PT engages in the development, manufacture, and distribution of pharmaceutical products. It operates through manufacturing and commercial segments. Manufacturing, which generates the majority of the revenue, is engaged in pharmaceutical manufacturing.
Rahway, United States of AmericaPharmaceuticals & Biotech
Ionis is unlocking the rapidly expanding potential of RNA- and DNA-targeted medicines to enable better futures for people living with serious diseases.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lungmore